Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Woo Young | - |
dc.contributor.author | Woo, Sang Uk | - |
dc.contributor.author | Seo, Jae Hong | - |
dc.contributor.author | Son, Gil Soo | - |
dc.contributor.author | Lee, Jae Bok | - |
dc.contributor.author | Bae, Jeoung Won | - |
dc.date.accessioned | 2021-09-07T07:57:59Z | - |
dc.date.available | 2021-09-07T07:57:59Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2011-10 | - |
dc.identifier.issn | 0973-1482 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/111512 | - |
dc.description.abstract | Background: Docetaxel and paclitaxel are likely to have different toxicity profiles, dose reduction and delays despite their similar medical results in breast cancer patients. Aims: This study examined retrospectively the incidence and severity of certain toxicities, dose reduction and delay of two taxanes. Materials and Methods: From January 2009 to June 2010, the incidence and severity of toxicities as well as the dose reduction, dose delay, granulocyte colony stimulating factor (G-CSF) in 54 patients with operable lymph node-positive (tumor stage T1, T2, or T3 and nodal stage N1 or N2) and high risk, node-negative (T2 or T3, N0) breast cancer without a distant metastases who received adjuvant chemotherapy - adriamycin, cyclophosphamide, docetaxel (TAC) and adriamycin, cyclophosphamide, paclitaxel (ACP)- were evaluated. Statistical Analysis Used: Mann-Whitney test and Fishers exact test. Results and Conclusion: The patients in the ACP group experienced more frequent peripheral neuropathy (P=0.025), nausea (P=0.033) than those in the TAC group. Febrile neutropenia was significant in TAC (P=0.001). Increasing age was associated with an increased risk of anemia (P=0.004), fatigue (P=0.009) and pain (P=0.003), and a decreasing body mass index was associated with an increased risk of febrile neutropenia (P=0.009). Dose reduction and delay occurred due to febrile neutropenia and an increase in aspartate aminotransferase (AST)/alanine aminotransferase (ALT). The dose reduction was only significant in the TAC group (P= 0.001). A taxane-based regimen should be chosen for breast cancer patients based on the pharmacokinetics, dosing schedule, clinical activity and toxicity profile that best meet the patients therapeutic needs and quality of life. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MEDKNOW PUBLICATIONS | - |
dc.subject | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | - |
dc.subject | PHASE-III TRIAL | - |
dc.subject | ADJUVANT CHEMOTHERAPY | - |
dc.subject | RISK | - |
dc.title | Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Woo Young | - |
dc.contributor.affiliatedAuthor | Woo, Sang Uk | - |
dc.contributor.affiliatedAuthor | Seo, Jae Hong | - |
dc.contributor.affiliatedAuthor | Son, Gil Soo | - |
dc.contributor.affiliatedAuthor | Lee, Jae Bok | - |
dc.contributor.affiliatedAuthor | Bae, Jeoung Won | - |
dc.identifier.doi | 10.4103/0973-1482.92004 | - |
dc.identifier.scopusid | 2-s2.0-84863071157 | - |
dc.identifier.wosid | 000299473200006 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, v.7, no.4, pp.412 - 415 | - |
dc.relation.isPartOf | JOURNAL OF CANCER RESEARCH AND THERAPEUTICS | - |
dc.citation.title | JOURNAL OF CANCER RESEARCH AND THERAPEUTICS | - |
dc.citation.volume | 7 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 412 | - |
dc.citation.endPage | 415 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | Dose delay | - |
dc.subject.keywordAuthor | dose reduction | - |
dc.subject.keywordAuthor | docetaxel | - |
dc.subject.keywordAuthor | febrile neutropenia | - |
dc.subject.keywordAuthor | paclitaxel | - |
dc.subject.keywordAuthor | peripheral neuropathy | - |
dc.subject.keywordAuthor | toxicity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.